In addition, it is presumed that steatohepatitic HCC with cirrhosis or severe fibrosis can be well-managed along with NASH itself through targeting of the STAT-1 signaling pathway, whereas NASH-HCC without cirrhosis or fibrosis would be treated independently through the STAT-3 signaling pathway. The gene discussed is STAT3; the disease is Cirrhosis.